bearish
Global Cord Blood (CO US): Gloomy Regulatory and Business Environment Explain Cheap Valuation
435 Views08 Apr 2022 23:47
SUMMARY
- Global Cord Blood (CO US) is facing regulatory and business environment uncertainty. China has not released any update on the new licenses of the country’s new cord blood bank.
- The company is seeing slower than expected business recovery and new subscriber addition is decelerating since Q1 FY22, mainly due to COVID-related restrictions.
- China’s birth rate dropped to a record low in 2021, thereby indicating sluggishness in the total addressable market of Global Cord.
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Top Quartile
Tina Banerjee
Global Healthcare Analyst
Price Chart(Sign Up to Access)
- Global Cord Blood (CO US): Fate Seems to Be Changing as New Growth Engine Added30 Apr 2022
- Global Cord Blood (CO US): Gloomy Regulatory and Business Environment Explain Cheap Valuation08 Apr 2022
- Global Cord Blood (CO US): No Immediate Respite Is Seen30 Jan 2022
- Global Cord Blood (CO US): Overhangs Persist; Weak Q2 Results Adds to Woe26 Nov 2021
x